GILEAD SCIENCES SL

Nurix Therapeutics appointed Roger Dansey, M.D., former Chief Development Officer and Chief Oncology Officer of Pfizer Oncology, to its board of directors.

South Africa becomes the first African nation to approve lenacapavir, a revolutionary HIV prevention injection that provides six months of protection per dose, marking a significant advancement in HIV prevention strategies.

Gilead will present new three-year interim data from the ASSURE study demonstrating that Livdelzi (seladelpar) may help stabilize or improve liver health in patients with primary biliary cholangitis.

Dublin-based biotech Meta-Flux has secured €1.8 million in seed funding from senior executives at Pfizer, Merck, and Gilead Sciences to expand its AI-powered drug development platform.

Nurix Therapeutics announced plans to initiate pivotal trials for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia patients in the second half of 2025, including both accelerated approval and confirmatory Phase 3 studies.

Expedition Therapeutics closed an oversubscribed $165 million Series A financing co-led by Sofinnova Investments and Novo Holdings to advance EXPD-101, a next-generation DPP1 inhibitor targeting neutrophilic inflammation in COPD.

Cartography Biosciences secured $67 million in Series B funding led by Pfizer Ventures to advance its lead T-cell engager CBI-1214 targeting colorectal cancer into Phase 1 trials.

Health Hope Pharma and Hanmi Pharm have granted Gilead Sciences exclusive global licensing rights to encequidar, a first-in-class P-glycoprotein inhibitor, specifically for virology applications.

Lupin Limited has received tentative FDA approval for its generic version of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, targeting a significant HIV treatment market.

Zimbabwe has been chosen as one of only ten countries worldwide to introduce lenacapavir, a groundbreaking HIV prevention drug developed by Gilead Sciences that requires only twice-yearly injections.